Purpose: To investigate the differential expression of stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP) and their correlation to mast cells, between patients diagnosed with superior limbic keratoconjunctivitis (SLK) and normal subjects.
S uperior limbic keratoconjunctivitis (SLK) is an ocular surface disorder characterized by unilateral or bilateral redundancy of the superior bulbar conjunctiva with inflammation of the superior tarsal and bulbar conjunctiva. 1 Our previous research has found an increased number of mast cells in the subepithelial stroma of patients with SLK. It is thus speculated that SLK may be a mast cell-related disorder. 2 Mast cells have a significant role in allergic and anaphylactic reactions. They circulate in an immature form until being committed to a specific site where full maturation develops. 3 Mast cells are commonly found in areas with communication to our environment, such as the skin, mouth, nose, lungs, and conjunctiva. Because the conjunctiva is constantly exposed to environmental factors, mast cells naturally play a key role in the pathogenesis of several ocular allergic diseases, such as seasonal allergic conjunctivitis, perennial conjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and contact lens-associated giant papillary conjunctivitis. 4 In addition to allergyrelated ocular diseases, mast cells have been found to be involved in the pathogenesis of pterygium and SLK. 2, 5 However, one of the major difference between these ocular inflammatory diseases is the location of the mast cell in the bulbar conjunctiva. Through immunohistochemical identification, mast cells were mainly found in the conjunctival epithelium in both VKC 6 and AKC 7 but not in SLK. In comparison, most mast cells in SLK are located in the conjunctival subepithelial stroma. 2 Mast cell inhibitors, such as cromolyn sodium and lodoxamide tromethamine, and immunomodulators, such as cyclosporine, were all reported as effective treatments [8] [9] [10] [11] of SLK. In addition to being a T-cell immunosuppressive agent, cyclosporine has also been shown to block mast cell proliferation and inhibit histamine release from mast cells. 12, 13 Confino and Brown 8 in 1987 reported that 6 of 8 patients with SLK showed marked improvement or complete resolution with topical cromolyn sodium 4% therapy. In 1995, Grutzmacher et al 9 reported 3 cases with typical SLK presentation. All of them were relieved symptomatically after 0.1% lodoxamide tromethamine treatment. Both cromolyn sodium and lodoxamide tromethamine are mast cell inhibitors, although through different mechanisms. Both cromolyn sodium and lodoxamide tromethamine can prevent mast cell degranulation and mediator release. Cromolyn sodium can also inhibit the activation of neutrophils, eosinophils, and monocytes, whereas lodoxamide tromethamine can reduce the infiltration of inflammatory cells such as eosinophils and mast cells. Because of our previous finding 2 and the effectiveness of mast cell inhibitors in the treatment of SLK from previous reports, 8, 9 the role of mast cells in the pathogenesis of SLK is to be further investigated.
Mechanisms involving promotion of mast cell migration and activation in SLK are presently unclear. Previously, stem cell factor (SCF), a cytokine that binds to the c-Kit receptor, was found to promote mast cell adhesion, migration, proliferation, and survival. 14 It also plays a critical role in hematopoiesis, spermatogenesis, and melanogenesis. 15 SCF is mainly produced by fibroblasts and endothelial cells, but epithelial cells have been shown to express SCF and/or c-Kit in a few studies as well. [16] [17] [18] [19] However, its role in the conjunctival tissue of SLK has not yet been reported.
Another important factor involved in the activation of mast cells is thymic stromal lymphopoietin (TSLP). 20, 21 TSLP is a protein that belongs to the cytokine family and is mainly produced by nonhematopoietic cells such as fibroblasts, epithelial cells, and stromal or stromal-like cells. 22 TSLP produced by epithelial cells could activate mast cells, inducing release of multiple proinflammatory cytokines and chemokines responsible for inflammatory reactions in atopic dermatitis, asthma, and ocular allergic diseases such as allergic conjunctivitis. [23] [24] [25] Nevertheless, its role in SLK is yet to be determined. The purpose of this study was thus to investigate whether SCF and TSLP are involved in patients with SLK by comparing the expression of SCF and TSLP between patients with SLK and normal subjects. The expression of SCF and TSLP was also correlated with the number of mast cells.
MATERIALS AND METHODS

Specimen Collection
Twenty-two specimens of superior bulbar conjunctiva were collected from 17 patients with medically refractory SLK visiting the Department of Ophthalmology at National Taiwan University Hospital from 1999 to 2008. Most (15 of 17) of our patients were treated by topical steroids for at least 6 months before their conjunctival resection surgery (range 6-18 months, mean 10.7 months). Two patients who did not use topical steroids were steroid responders. Thus, other medications except steroids were used. The topical steroids that were used included 0.1% fluorometholone (Flucon, Alcon Laboratories Pty Ltd, Belgium), 0.1% betamethasone disodium phosphate (Rinderon, Taiwan Shoinogi Co Ltd, Taiwan), or an ointment with a combination of dexamethasone, neomycin, and polymyxin B (Maxitrol ointment, Alcon Laboratories Pty Ltd, Belgium). Artificial tears were also used on all of our patients (range, 4-18 months, mean, 11.2 months). Mast cell inhibitor (Zaditen, Novartis Pharmaceuticals, Canada) was used in 4 of 17 patients for a mean of 5.7 months (range, 3-14 months). Two of 17 patients also instilled fortified acetylcysteine eye drops (range, 2-4 months; mean, 3.0 months). All surgeries were performed by one surgeon (F.R.H.). The surgical technique has been previously described. 2 Normal conjunctival tissue that served as controls was obtained from patients with excess conjunctiva found at the end of retinal or extracapsular cataract extraction surgeries. The conjunctival specimens of both SLK and control groups were sent to the Department of Pathology for routine paraffin embedding. Paraffinized blocks in 5-mm sections from both patients with SLK and controls were used in immunohistochemistry (IHC) experiments. This study was approved by the Institutional Review Board of the National Taiwan University Hospital (NTUH-REC-9461700634) and registered under ClinicalTrials.gov as NCT00167050.
Immunohistochemical Method
To enhance tissue adhesion, 5-mm-thick sections were mounted on pretreated glass slides (Vectabond; Vector Laboratories, Burlingame, CA). After drying, the paraffin was removed with xylene, and the sections were rehydrated by passing them through decreasing concentrations of ethanol. After antigen retrieval in 0.1% trypsin solution at 37°C for 15 minutes and quenching of endogenous peroxidase activity in 3% hydrogen peroxidase, the paraffin sections were blocked with serum for 60 minutes before being incubated with anti-human tryptase (#M7052, Dako, Glostrup, Denmark), SCF (#ab52603, Abcam, Cambridge, United Kingdom), and TSLP (#13778-1-AP, Proteintech, Chicago, IL) overnight at 4°C. After they were incubated with biotinylated secondary antibody for 60 minutes at room temperature and washed with phosphate-buffered saline 3 times, the paraffin sections were incubated with Vectastain ABC Kit reagent (Vector Laboratories, Burlingame, CA) for 30 minutes. Antibody detection was then achieved with 3,39 diaminobenzidine peroxidase substrate solution for 20 minutes. Sections were all counterstained with hematoxylin to facilitate tissue orientation, and then mounted. For negative controls, the primary antibody was omitted. The conjunctival epithelial and subepithelial stromal immunostaining was graded 0 to 3 according to the following scales of immunointensity: grade 0, no staining; grade 1, minimal staining; grade 2, moderate staining; and grade 3, severe staining. 26 All the subjective grading of the IHC staining was reviewed under a light microscope by 2 independent reviewers who were masked to the subject groups. High consistency of IHC grading was noted between these 2 reviewers.
Statistical Analysis
All the data were reported as mean 6 SD. Statistical significance of the data was assessed using the Wilcoxon signed-ranked test and t test. P , 0.05 was considered to indicate a statistically significant difference.
RESULTS
Higher Immunostaining of SCF and TSLP in Conjunctival Epithelium in Patients With SLK
In the surgical specimens of patients with SLK, higher immunostaining intensity of SCF was found in the conjunctival epithelium (average grading 6SD, 2.8 6 0.8) than that in the conjunctival subepithelial stroma (1.4 6 0.7). Immunostaining of TSLP in the conjunctival epithelium (2.5 6 0.6) was also more prominent than that in the conjunctival subepithelial stroma (1.6 6 0.7) ( Fig. 1) . Compared with normal controls (1.8 6 0.8), SCF staining in the conjunctival epithelium was significantly more intense in patients with SLK (P , 0.05, Wilcoxon signed-ranked test). This difference was not noted for conjunctival subepithelial stroma (normal subjects, 1.0 6 0.7). The immunostaining pattern of TSLP between SLK and normal subjects was similar to that of SCF (TSLP staining of normal subjects in conjunctival epithelium and subepithelial stroma, 1.0 6 0 and 1.2 6 0.4, respectively; P , 0.05, Wilcoxon signed-ranked test; Fig. 2 ).
The Number of Mast Cell in Conjunctival Subepithelial Stroma and Immunostaining Intensity of SCF and TSLP Were Positively Correlated in SLK Patients
Protein expression of SCF and TSLP in the conjunctival epithelium or subepithelial stroma was compared with the number of "tryptase (+)" mast cells in patients with SLK. There was a positive correlation of immunostaining intensity of SCF with the numbers of mast cells, but it was not statistically significant [42.0 6 11.3 and 46.3 6 14.1 mast cells per 10 high-power field (HPF) for grade 2 and grade 3 immunostaining of SCF in the epithelium; 42.1 6 12.4, 49.8 6 16.1, and 53.0 6 6.0 mast cells per 10 HPF for grade 1, grade 2, and grade 3 immunostaining of SCF in the subepithelial stroma, respectively; P . 0.05 between groups, t test; Fig. 3A, B ]. However, higher immunostaining intensity of TSLP was significantly correlated with the number of "tryptase (+)" mast cells (34.5 6 10.5 and 47.0 6 8.3 mast cells per 10 HPF for grade 2 and grade 3 immunostaining of TSLP in the epithelium, respectively; P = 0.01, t test; Fig.  3C ). A statistically significant correlation of grade 1 and grade 2 TSLP expression in conjunctival subepithelial stroma with the number of mast cells in the SLK group was also found (grade 1, 35.0 6 9.2; grade 2, 52.9 6 9.6; P , 0.001, t test; Fig. 3D ).
DISCUSSION
The migration and activation of mast cells in the conjunctival epithelium is a hallmark histopathologic finding in severe chronic allergic conjunctivitis, AKC, and VKC. 4 Involvement of mast cells in SLK was first observed by our group in our previous study in 2008. 2 Previously, Theodore and Ferry 27 had reported the finding of scarce cellular infiltrations with neutrophils predominant in the superior bulbar conjunctiva of patients with SLK. In addition, Donshik et al 28 found that only a few inflammatory cells-neutrophils, lymphocytes, and plasma cells-are present in the stroma of the superior bulbar conjunctival of SLK surgical specimens. This finding was not significantly different from cells of normal controls. We also found no significant difference in the number of T and B lymphocytes between SLK and control groups. 2 However, a high number of mast cells were found in the subepithelial stroma of patients with SLK. Therefore, we speculate that SLK may be an inflammatory disorder related to mast cell degranulation instead of a cellmediated inflammation. Although Confino and Brown 8 in 1987 and Grutzmacher et al 9 in 1995 mentioned the effectiveness of mast cell inhibitors in the treatment of SLK, the pharmacologic or pathologic mechanisms involved was not described. Based on our previous results 2 in 2008, we FIGURE 1. Photomicrographs showing IHC stain results using antibodies against human SCF and TSLP between SLK and control groups. A and C, Conjunctival specimen from the normal control showed normal epithelial thickness with mild SCF and TSLP immunostaining, respectively (original magnification, ·400). B and D, One of the specimens in the SLK group showed proliferation and thickening of the conjunctival epithelium with significant SCF and TSLP immunostaining, respectively (original magnification, ·400).
prescribed mast cell inhibitors routinely as an adjunctive treatment in patients with SLK. According to our unpublished data, mast cell inhibitors ameliorated the symptoms in cases with mild SLK but not as well in moderate and severe cases. In this study, we have found a significant increase in the expression of SCF and TSLP, which may possibly contribute to mast cell migration and activation in patients with SLK. There were 4 of the 17 patients previously treated with mast cell inhibitors in our study group. These specimens showed fewer mast cells and less SCF and TSLP immunostaining, although without statistical significance.
Previously, factors promoting mast cell migration, such as transforming growth factor b, 29,30 platelet activating factor, 31 C3a and C5a, 32, 33 etc, were secreted by cells of hematopoietic origin. SCF, however, can be also be secreted by cells of epithelial origin, such as dermal, 15 corneal, 17 and conjunctival epithelial cells. 34 The SCF/c-Kit system also plays a role in corneal wound healing through promoting epithelial adhesion. 17 Overexpression of SCF by fibroblasts was found in the head of pterygium tissue. 34 Coincidentally, an increased number of mast cells were also found in pterygium tissue. Nakagami et al 5 thus proposed that nonallergic stimuli Correlation of the amount of conjunctival subepithelial stromal mast cells with SCF and TSLP immunostaining intensity in patients with SLK. A and B, SCF immunostaining in conjunctival epithelium and conjunctival subepithelial stroma, respectively. A positive, but not statistically significant, correlation between the number of mast cells and SCF immunointensity grading was found. C and D, TSLP immunostaining in conjunctival epithelium and conjunctival subepithelial stroma, respectively. Both showed a significant correlation between the number of mast cells and TSLP immunointensity grading (*P , 0.05).
could cause migration and activation of mast cells, which may be involved in enhancing angiogenesis and tissue remodeling. In our study, SCF was significantly overexpressed in the conjunctival epithelium of patients with SLK compared with normal subjects. We also noted an increase in the number of mast cells in the conjunctival tissue, although not statistically significant. This indicates a possible role of SCF in promoting mast cell migration in patients with SLK.
Mast cell activation by TSLP had been previously shown. Allakhverdi et al 35 found that human epithelial cells may release TSLP after trauma or inflammation. The TSLP subsequently activates mast cells. Mechanical stimulation or trauma had been previously proposed as a cause of SLK. 36, 37 Therefore, removal of redundant or loose conjunctival tissue by conjunctival resection has been effective in alleviating symptoms of SLK. 2, [38] [39] [40] Mechanical trauma caused by abrasion or rubbing of the redundant superior bulbar conjunctival with the tarsal conjunctiva not only results in increased keratinization of the conjunctival epithelium but may also induce release of inflammatory mediators. In this study, we found increased TSLP immunointensity in the conjunctival epithelium of patients with SLK. A statistically significant correlation was also noted between the grading of TSLP in the conjunctival epithelium and subepithelial stroma and the number of mast cells in the subepithelial stroma of patients with SLK. To the best of our knowledge, this is the first study showing a correlation between mast cells and TSLP in patients with SLK. We hypothesize that SCF and TSLP may be secreted by conjunctival epithelial cells resulting from microtrauma due to redundancy of the superior bulbar conjunctiva and may be the factors possibly inducing the migration or activation of mast cells.
Although our novel finding that SCF and TSLP may be the cytokines promoting mast cell migration and activation in SLK, there are some limitations and drawbacks of our study. SLK is a relatively rare disease. Because only medically refractory cases would require conjunctival resection, we only had 17 patients with SLK in total who were collected over nearly a decade. Thus, all specimens were preserved in paraffin blocks, which prohibited adequate polymerase chain reaction or Western blot analysis. We hope that a larger sample size in the future can provide more information and better statistical analysis. Future experimentation with human conjunctival cell cultures or developing animal models of SLK will better enhance our understanding of this chronic ocular surface irritation problem.
In conclusion, overexpression of SCF and TSLP in the conjunctival epithelium with significant correlation between TSLP grading and the number of mast cells was noted in patients with SLK. SCF and TSLP may be involved in promoting mast cell migration and activation that contributed to the pathogenesis of SLK. Treatment strategies targeting mast cells and their activation or migration factors may be helpful in future management of SLK.
